Beijing News (Reporter Wang Kala) On June 27, Ipsen, a global biopharmaceutical company in the specialty drugs field, announced that the six-month ultra-long-acting formulation of Triptorelin Pamoate for Injection (brand name: Decapeptyl) has been approved for marketing in China, for the treatment of locally advanced or metastatic prostate cancer.
Prostate cancer is one of the most common malignant tumors in the urinary and reproductive systems of elderly men. Its incidence and mortality rank 2nd and 5th, respectively, in the global spectrum of male malignant tumor incidence and mortality, and rank 6th and 7th, respectively, among Chinese men. The development of prostate cancer is closely related to testosterone levels (i.e., androgen levels). Lowering testosterone levels can suppress the progression of prostate cancer. Androgen deprivation therapy (ADT, also known as endocrine therapy) is the standard treatment for locally advanced and metastatic prostate cancer. According to the "Chinese Expert Consensus on Testosterone Management in Prostate Cancer 2021 Edition," during ADT treatment, achieving a deeper reduction of testosterone to <20ng/dl (a hormone unit, read as "nanograms per deciliter") may serve as a reference indicator for better clinical prognosis and treatment adjustment. Meanwhile, prostate-specific antigen (PSA), as a tumor marker for prostate cancer, exhibits good sensitivity and specificity, aiding in the early screening and diagnosis of prostate cancer. In standardized disease management, both testosterone and PSA are crucial predictive indicators for the survival of prostate cancer patients.
As the primary drug for ADT treatment, Decapeptyl (Dafelin) has been used in the field of prostate cancer treatment for many years and is a potent inhibitor of gonadotropin secretion. Research results confirm that the six-month formulation of Decapeptyl can reduce testosterone levels to 20 ng/dl, effectively lower PSA levels to below 4 ng/ml, and maintain stability. Compared with the traditional one-month formulation of Decapeptyl, the longer-acting formulation has gradually gained clinical recognition. The six-month formulation of Decapeptyl significantly reduces the number of injections and follow-up visits for patients, simplifies the care process, decreases unnecessary visits by 46.8%, thereby reducing overall costs, further alleviating the burden of medical visits, and improving patients' quality of life. Ipsen's six-month formulation of Decapeptyl has over 10 years of clinical application history worldwide, with efficacy, tolerability, and safety consistent with the one-month and three-month formulations.
Proofread by Baoqing Liu